Bupropion Treatment for Youth Smoking Cessation

June 23, 2006 updated by: University of Arizona
The purpose of this study is to 1) evaluate the safety and efficacy of two doses of bupropion SR (150mg/day and 300mg/day) when compared to placebo, as an aid to smoking cessation in adolescents and 2) to examine which factors, such as medication adherence, nicotine dependence, and motivation to quit, affect treatment outcome.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arizona
      • Tucson, Arizona, United States, 85724
        • University of Arizona

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 17 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 14 to 17 years of age
  • Smoked at least 6 cigarettes per day
  • Exhaled CO greater than or equal to 10 ppm
  • Made at least two previous quit attempts
  • Weighed at least 90 pounds
  • Able to read English at least the 6th grade level
  • Motivated to quit smoking as evidenced by willingness to commit to study protocol requirements for the duration of the study
  • provided active parental consent and youth assent

Exclusion Criteria:

  • Current use of tobacco products other than cigarettes, unless willing to abstain from these products for the study duration
  • Current use of other treatments for smoking cessation
  • History or current diagnosis of panic disorder, psychosis, bipolar disorder, or eating disorder
  • History of abuse or dependence on alcohol or other recreational or prescription drugs in the three months preceding the study
  • Current evidence of clinical depression or Attention Deficit/Hyperactivity Disorder
  • Use of any psychoactive drug and/or any type of antidepressant with in four weeks of the treatment phase of the study
  • Predisposition to seizure or tic disorders or a personal history of a seizure disorder, family history of seizure disorders, or treatment with medication or therapies that increase the risk of seizures
  • Significant history of or current clinical evidence of cardiovascular disease
  • (Females)Pregnancy (urine pregnancy test), lactation or, if sexually active, unwillingness to use a medically acceptable form of contraception for the duration of the study
  • Only one member of a household was allowed to participate in the study concurrently.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Double

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Biochemically verified 7 day point prevalence abstinence from smoking.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Arizona

Investigators

  • Principal Investigator: Myra L. Muramoto, MD MPH, University of Arizona

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Completion

April 1, 2003

Study Registration Dates

First Submitted

June 23, 2006

First Submitted That Met QC Criteria

June 23, 2006

First Posted (Estimate)

June 27, 2006

Study Record Updates

Last Update Posted (Estimate)

June 27, 2006

Last Update Submitted That Met QC Criteria

June 23, 2006

Last Verified

June 1, 2006

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 3R01CA077081-04S1 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Nicotine Dependence

Clinical Trials on bupropion SR

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe